|Market Cap||Dividend Yield (Annualized)|
|0.088L 0.088 H|
|52 WEEK HIGH LOW|
|0.049L 0.2 H|
|52 W H/L||0.200/0.049|
|NPAT After Abnormal Items||-19.874M|
|Cash and Cash Equivalents||40.73M|
|Price/Gross Cash Flow||-9.75|
|Dividend Yield Excluding Special||0.00%|
|Gross DPS (AUD)||0|
|Gross Dividend Yield (Annualized)||0.00%|
|Net Tangible Asset (NTA)||0.02|
|Net Profit Margin (%)||-189.37%|
|Gross Cash Flows Per Share||-0.01|
|Sales Per Share||0.01|
|Book Value Per Share||0.03|
A global company, ImpediMed Limited (ASX:IPD) is a world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies. These are used in the noninvasive clinical assessment and monitoring of fluid status and tissue composition.
ImpediMed was founded and is headquartered in Brisbane, Australia. Operation run in the United States and Europe.
The Company’s devices accurately and noninvasively measure a patient’s total body water, and extracellular and intracellular fluid volumes to aid in the assessment and interventions for chronic diseases.
ImpediMed, along with its subsidiaries have pioneered the use of BIS technology. The first commercially available BIS device was produced in 1990.
Notably, the Company’s L-Dex® device was the first FDA-cleared medical technology to use BIS for the assessment of lymphedema. Currently, the use of L-Dex is now recommended in clinical practice guidelines of research centers and professional organizations across the country.
In 2017, ImpediMed launched SOZO®, the world’s most advanced BIS device. It is an FDA-cleared, CE-marked and ARTG-listed digital health platform. SOZO® helps in the early detection of secondary lymphedema, offers fluid status for patients living with heart failure and enables measurement and tracking of various body composition parameters.
A single, powerful SOZO® reading allows clinicians across multiple specialties to provide individualized, proactive care that can help improve patient outcomes.
The Company is exploring the use of its advanced bioimpedance technology for a wide range of commercial applications such as General health and weight management, bone content and protein-calorie malnutrition.
Unit 1, 50 Parker Court, PINKENBA, QLD, AUSTRALIA, 4008
|Ex-Date||Net Dividend||Frank Flag||Period End Date||Type||Payable|
|Event Type||Event Date||Event Year|